REXADEV

EUIPO EUIPO 2017 Trademark registered

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The Union trademark REXADEV was filed as Word mark on 02/01/2017 at the European Union Intellectual Property Office.
It was registered as a trademark on 06/27/2017. The current status of the mark is "Trademark registered".

Trademark Details Last update: February 9, 2024

Trademark form Word mark
File reference 016311276
Application date February 1, 2017
Publication date March 20, 2017
Entry date June 27, 2017
Expiration date February 1, 2027

Trademark owner

One Amgen Center Drive
91320-1799 Thousand Oaks,
US

Trademark representatives

2Amsterdam Eduard van Beinumstraat 10 3rd Floor 1077 CZ Amsterdam NL

goods and services

5 Pharmaceutical preparations and biosimilars; pharmaceutical preparations, biosimilars and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; pharmaceutical preparations, biosimilars and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; pharmaceutical preparations, biosimilars and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis; pharmaceutical preparations, biosimilars and substances used for the treatment of small bowel lesions, Hermansky-Pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, Pyoderma Gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma

Trademark history

Date Document number Area Entry
November 6, 2023 Change Representative, Published

ID: 11016311276